Results 221 to 230 of about 374,943 (358)
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
Arthritis &Rheumatology, EarlyView.Objective
The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods
This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian +35 morewiley +1 more sourceDiagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injury
Hepatology, EarlyView., 2022 Diagnostic and prognostic ability of urinary NGAL in patients with cirrhosis and AKI. Abstract Background and Aims
Acute kidney injury (AKI) commonly occurs in patients with decompensated cirrhosis. Urinary neutrophil gelatinase–associated lipocalin (uNGAL) could help discriminate between different etiologies of AKI.Carmine Gambino, Salvatore Piano, Matteo Stenico, Marta Tonon, Alessandra Brocca, Valeria Calvino, Simone Incicco, Nicola Zeni, Roberta Gagliardi, Chiara Cosma, Martina Zaninotto, Patrizia Burra, Umberto Cillo, Daniela Basso, Paolo Angeli +14 morewiley +1 more sourceDiagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Arthritis &Rheumatology, EarlyView.Objective
Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 ...Jian Yue, Courtney E. LeSon, Casey A. Rimland, Kailey Brodeur, Rachel Weng, Evan E. Hsu, Michael T. Lam, Manpreet Meyer, Seigo Okada, Andrew L. D. Hsu, Musaab A. Alhezam, Megan M. Perron, Olha Halyabar, Fatma Dedeoglu, Peter A. Nigrovic, Akiko Shimamura, R. Grant Rowe, Megan A. Cooper, Tiphanie P. Vogel, Miriah Gillispie‐Taylor, Rosemary Peterson, Clara Lin, Katherine D. Nowicki, Kaylee Dollerschell, Taizo A. Nakano, Roxane Labrosse, Alexis‐Virgil Cochino, Andreea Ioan, Leonardo Oliveira Mendonca, Samar Freschi Barros, Jorge Kalil, Javier Perez‐Rojas, Alicia Diaz‐Kuan, Eric S. Sobel, Taha Moussa, Samuel Shang Ming Lee, Li Wearn Koh, Archana Khan, Sodality Sutnga, Raju Khubchandani, Walaa Shoman, Yasmine El Chazli, Benzeeta Pinto, Chengappa Kavadichanda, Roshini S. Abraham, Xiangwei Sun, Qing Zhou, Gsrsnk Naidu, Aman Sharma, Carl Esperanzate, Daniel L. Kastner, Ivona Aksentijevich, Susan J. Kelly, Michael Hershfield, Teresa K. Tarrant, Pui Y. Lee +55 morewiley +1 more sourceSerum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy
Hepatology, EarlyView., 2022 Serum bile acid levels predict outcomes in patients with biliary atresia who achieve normalized bilirubin levels after Kasai portoenterostomy. Abstract Background and Aims
In biliary atresia, serum bilirubin is commonly used to predict outcomes after Kasai portoenterostomy (KP).Sanjiv Harpavat, Kieran Hawthorne, Kenneth D. R. Setchell, Monica Narvaez Rivas, Lisa Henn, Charlotte A. Beil, Saul J. Karpen, Vicky L. Ng, Estella M. Alonso, Jorge A. Bezerra, Stephen L. Guthery, Simon Horslen, Kathy M. Loomes, Patrick McKiernan, John C. Magee, Robert M. Merion, Jean P. Molleston, Philip Rosenthal, Richard J. Thompson, Kasper S. Wang, Ronald J. Sokol, Benjamin L. Shneider, for Childhood Liver Disease Research Network (ChiLDReN) +22 morewiley +1 more sourceNext endoscopic approach for acute lower gastrointestinal bleeding without an identified source on colonoscopy: upper or capsule endoscopy? [PDF]
, 2019 Tomonori Aoki, Naoyoshi Nagata, Atsuo Yamada, Takuro Shimbo, Yuuki Matsushita, Akira Shimomura, S. Kobayashi, Shiori Moriyasu, Ryota Niikura, Toshiyuki Sakurai, Yoshihiro Hirata, Junichi Akiyama, Naomi Uemura, Kazuhiko Koike +13 moreopenalex +1 more sourceCorrection: Transarterial embolization for acute lower gastrointestinal bleeding: a retrospective bicentric study. [PDF]
Radiol MedTiralongo F, Perini D, Crimi L, Tomassoni MT, Braccischi L, Castiglione DG, Modestino F, Vacirca F, Falsaperla D, Libra FMR, Palmucci S, Foti PV, Lionetti F, Mosconi C, Basile A. +14 moreeuropepmc +1 more sourceAvailability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres
British Journal of Clinical Pharmacology, EarlyView.Introduction
Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod +18 morewiley +1 more source